| Similar Articles |
|---|
 |
The Motley Fool
September 7, 2006
Brian Lawler |
SkyePharma Makes a Deal The pharmaceutical sells European rights to a promising asthma drug. With approval not guaranteed, and a cutthroat market for asthma drugs, this deal looks pretty good for Skye overall.   |
Chemistry World
September 25, 2013
Phillip Broadwith |
New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets. |
The Motley Fool
December 28, 2004
Charly Travers |
It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed... |
The Motley Fool
December 28, 2006
Brian Lawler |
Money Falling From the Skye Investors are wondering what to make of drug developer SkyePharma announcing yesterday that it was raising more cash via financing and also upping the costs of its Flutiform asthma treatment development program. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
January 27, 2005
Wherrett & Yelovich |
Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look. |
